What are the labeling requirements for medical devices in China?

China’s National Medical Products Administration (NMPA, 国家药品监督管理局, guójiā yàopǐn jiāndū guǎnlǐ jú) mandates that all medical devices sold in China carry Chinese-language labels with no exceptions — a requirement that drives an estimated $8,000 to $25,000 in labeling re-engineering costs per device SKU for foreign manufacturers entering the market. With over 28,000 medical device registration certificates active in China as of 2025 and a market growing at 12–15% annually, getting the label right is one of the first — and most frequently failed — regulatory hurdles for international companies.

Direct Answer: What Are the Labeling Rules for Medical Devices in China?

Every medical device sold in the People’s Republic of China must bear a physical label in simplified Chinese characters. Foreign-language-only labels are not accepted under any circumstances — even for imported devices destined for specialist hospitals or private clinics. The Chinese label may include English or other languages alongside Chinese, but Chinese must be the primary language and must contain all mandatory information elements.

The core requirements are established by:

• Decree 739 (Regulations on the Supervision and Administration of Medical Devices) — the foundational legal framework, particularly Article 39
• NMPA Order No. 12 (2014) — Regulations on the Management of Medical Device Instructions and Labels, which provides detailed content and formatting rules
• GB 9706.1-2020 — the Chinese adoption of IEC 60601-1 for electrical medical device safety labeling
• YY/T 0466.1 — the Chinese equivalent of ISO 15223-1, governing symbols used on medical device labels

Failure to comply with these requirements triggers Article 88 of Decree 739, which empowers NMPA inspectors to issue warnings, fines, and — in cases where labeling deficiencies lead to safety incidents — fines of up to RMB 300,000 (approximately USD 42,000) plus mandatory product recalls.

Regulatory Basis: The Legal Framework Behind China’s Labeling Rules

Understanding the regulatory architecture helps foreign manufacturers anticipate where compliance risk is highest. The labeling regime rests on four legal pillars:

1. Decree 739 — The Superseding Regulation

Formerly State Council Decree 650 (2014, revised 2017), the current Decree 739 (2021 revision) is the highest-level regulation governing medical devices in China. Article 39 specifically requires that medical device labels and instructions for use (IFU) comply with NMPA standards and contain all prescribed information. The regulation also empowers NMPA to issue more detailed administrative orders — which is precisely what Order No. 12 does.

2. NMPA Order No. 12 (2014) — The Detailed Rulebook

Order No. 12, formally titled “Regulations on the Management of Medical Device Instructions and Labels,” remains the most operationally relevant document for labeling teams. It specifies:

• The exact information elements that must appear on labels and IFUs
• That all text must be in Chinese (Article 3)
• That labels must be legible, durable, and appropriate to the device’s intended use environment
• The classification of label changes as minor, moderate, or major (affecting approval pathway)

3. Product-Specific Standards (GB, GB/T, YY/T Series)

Beyond the general requirements, individual device categories are governed by mandatory national standards (GB) and recommended industry standards (YY/T). The most cross-cutting is GB 9706.1-2020, the general safety standard for electrical medical equipment, which incorporates IEC 60601-1 requirements for markings, labels, and accompanying documents. For label symbols, YY/T 0466.1 adopts ISO 15223-1 but adds China-specific requirements (see Symbols section below).

4. UDI Regulatory Framework

China’s Unique Device Identification (UDI) system, implemented in phases beginning 2019, now covers Class II and Class III devices. The UDI must appear in both Human Readable Interpretation (HRI) format and as an AIDC (barcode or QR code). As of 2025, Class III devices must carry UDI on all levels of packaging; Class II devices must carry it on the unit-of-use package.

Required Label Content: What Information Must Appear

NMPA requires the following elements on the label of every medical device sold in China. Where applicable, the required Chinese terminology and pinyin are provided:

Label Format Standards: Font Size, Symbols, and Color Coding

China’s labeling regulations go beyond content requirements — the format and presentation of label information are also explicitly governed.

Font and Legibility

NMPA Order No. 12 Article 7 requires that label text be “clear, legible, and durable.” In practice, this means:

• Chinese characters must be in standard simplified script (simplified Chinese, not traditional)
• Minimum font size is not specified by law, but NMPA inspectors typically expect the warning and caution text to be at least 6 pt or equivalent readable size on the smallest package
• Warning text must be visually distinct — bold, colored, or boxed — and must not be hidden inside folds or under other labels
• Background contrast must be sufficient; gray-on-gray or low-contrast schemes are regularly rejected during label review

Symbols on Labels

China accepts the use of standardized symbols from ISO 15223-1 (via YY/T 0466.1), but with an important caveat: a Chinese-language legend explaining the symbol must accompany it on the label or on the immediate package. A symbol alone — without Chinese text explanation — is not compliant.

For custom symbols (not from ISO 15223-1 or GB/T series), the manufacturer must receive NMPA acceptance through the registration or change process. This is a common point of friction for foreign manufacturers accustomed to the EU’s more flexible approach to proprietary symbols.

Color Coding

While China does not have a mandatory color-coding standard for medical device labels (unlike, for example, the EU’s MDR Annex I requirements for specific hazard colors), certain conventions are widely enforced:

• Warnings: Typically red or orange text/symbols
• Cautions: Yellow background or amber text
• Mandatory actions (sterile, single-use): Blue or white on specified backgrounds
• Prohibition symbols: Red circle-slash per GB/T 191

Durability Testing

Labels must survive the device’s intended storage, transportation, and use conditions. For reusable devices, labels must remain legible after repeated cleaning and sterilization cycles. NMPA inspectors may request evidence of label durability testing during on-site audits of manufacturing facilities — a requirement that catches many first-time applicants off guard.

Package Insert (Instructions for Use) Requirements

The package insert — or Instructions for Use (IFU) — is treated as a regulatory document distinct from the product label, though many content elements overlap. NMPA Order No. 12 specifies that IFUs must contain:

1. Product name (matching the registration certificate)
2. Model and specifications — all variants covered by the registration
3. Intended use — must match the approved scope of the registration certificate exactly
4. Structure and composition — materials, components, functional principle
5. Performance parameters — technical specifications with measurement units
6. Operating instructions — step-by-step usage in Chinese
7. Precautions and warnings — must include all contraindications, side effects, and risks
8. Storage and handling — temperature, humidity, light exposure limits
9. Maintenance and calibration — intervals and procedures
10. Disposal instructions — including environmental considerations
11. Registration certificate number — 注册证编号
12. Production license number — for Class II/III devices
13. Manufacturer contact — name, address, phone (including overseas)
14. After-sales service contact — in China (usually the China Legal Agent)

All IFU content must be in Chinese. An English version may be provided alongside as a reference document, but the Chinese version is the legally binding one. NMPA inspectors compare IFU content against the registered technical documentation during post-market surveillance; discrepancies — even seemingly minor ones — can result in non-compliance findings.

Special Labeling by Device Class

The stringency of labeling requirements scales with device risk classification, following China’s Class I (low risk), Class II (moderate risk), Class III (high risk) framework:

Class III devices face the most rigorous label scrutiny. NMPA expects that the label and IFU submitted during registration review are exactly what will appear on the marketed product — post-approval changes are costly and time-consuming. Class I devices enjoy the lightest touch: manufacturers file a record of their label with the local Municipal Medical Products Administration, and no substantive pre-market review occurs. However, Class I labels are still subject to post-market inspection, and non-compliance carries the same penalties under Article 88.

Electronic Labeling (e-Labeling) Rules

Foreign manufacturers accustomed to the European or U.S. regulatory frameworks often ask whether China accepts electronic labeling — that is, a QR code or web link on the device or package that directs users to a digital version of the label or IFU. The answer is generally no.

China is significantly more restrictive on e-labeling than the EU MDR or the U.S. FDA. The default requirement is that physical labels on the device and its packaging are mandatory. Electronic labeling is not accepted as a substitute for physical labels, except in two narrow cases:

1. Implantable devices — Certain implantable devices may use a card or patient-implant-identification system with a QR code linking to the full IFU, provided a physical IFU summary is also included in the packaging.
2. Software as a Medical Device (SaMD) — For pure software products, the label is typically the application interface or a downloadable PDF from the manufacturer’s China-hosted website, provided the content meets all Order No. 12 requirements.

For all other devices — including in vitro diagnostics (IVDs), consumables, surgical instruments, and capital equipment — the full label and IFU must be physically present on or in the product packaging. Chinese hospitals and distributors generally lack the infrastructure to reliably access online IFUs at the point of use, and NMPA has not signaled any intention to relax this requirement.

Label Changes and Approvals: When NMPA Must Be Notified

One of the most operationally challenging aspects of China medical device regulation is the classification of label changes. The change category determines whether you can simply update the label and notify NMPA, or whether you must go through a formal approval process that can take 6–12 months.

Minor Changes (Notification within 30–60 days)

• Manufacturer address update (same legal entity, same physical factory)
• Contact information updates (phone number, email, website)
• Minor editorial corrections (typos, grammar)
• Production license number update (renewal of existing license, no scope change)

Minor changes require the manufacturer to file a record with NMPA within 30–60 days of the label update. No pre-approval is needed.

Moderate Changes (NMPA Approval Required)

• Changes to warnings, cautions, or contraindications
• Changes to intended use statements
• Addition or removal of model numbers from the label
• Changes to storage conditions or expiry dates
• Changes to sterilization method or claims

Moderate changes require submission of a registration certificate change application to NMPA. Review timelines are typically 60–120 working days, and the device may not be sold with the new label until approval is received.

Major Changes (New Registration May Be Required)

• Change of manufacturer name (different legal entity)
• Change of intended use that expands the indication
• Change from sterile to non-sterile (or vice versa)

These changes may require a full new registration application (or significant amendment), with review times of 6–18 months.

Common Labeling Pitfalls Foreign Manufacturers Make

Based on NMPA warning letters, rejection notices, and field feedback from China regulatory consultants, the following mistakes recur frequently:

1. Using traditional Chinese characters instead of simplified Chinese. Hong Kong and Taiwan use traditional script; China’s mainland requires simplified. This single error appears in roughly 30% of first-time foreign submissions.
2. Providing English-only labels with a sticker overlay in Chinese. NMPA expects the base label to be Chinese; adhesive overlays are considered temporary and may be rejected, especially if they peel or shift.
3. Omitting the China Legal Agent (CLA) details. The CLA’s name and address must appear on the label — not just in the registration file.
4. Incorrect registration certificate number format. The string must exactly match NMPA’s format (e.g., 国械注进2024XXXXX). A single transposed digit or character renders the label non-compliant.
5. Using unapproved symbols. Custom symbols without NMPA acceptance, or ISO symbols without an accompanying Chinese legend, are frequent findings during inspections.
6. Forgetting the UDI. Class III devices without UDI on all packaging levels are increasingly flagged during port inspection.
7. Inconsistent IFU and label content. When the IFU mentions a warning or specification that conflicts with the label — or vice versa — NMPA treats this as a compliance deficiency.
8. Assuming e-labeling is acceptable. Foreign teams accustomed to EU MDR’s e-labeling flexibility (under EN ISO 20417) frequently design labels that are too sparse, expecting the full label to be accessed online. This does not work in China.
9. Failing to budget for label durability testing. Manufacturers who skip label abrasion, solvent-resistance, or autoclave-cycle testing often receive deficiency letters during technical documentation review.
10. Treating label changes too casually. What a foreign team considers a “minor wording update” may be classified as a moderate change requiring NMPA approval. This miscalculation can delay market supply by 6+ months.

The financial impact of labeling non-compliance extends beyond fines. A recall triggered by labeling deficiencies costs an average of $50,000–$200,000 for logistics, replacement labeling, regulatory notification, and brand damage. Preventative investment in label compliance — comprehensive pre-submission review by a qualified China regulatory consultant — typically costs $5,000–$15,000 and can eliminate the majority of these risks.

Where to Go From Here

Based on what you just read:

• Ready to act? Read [guide: SLUG-TO-BE-FILLED]
• Still comparing? See [comparison: SLUG-TO-BE-FILLED]
• Need numbers? Try [tool: SLUG-TO-BE-FILLED]

— China Gateway 360 —
Remote China market entry support, built around execution.